

Title:

Precision Biologics announces publication of article in science journal *CANCERS*, July 20, 2026.

Body:

Precision Biologics announces that an article, entitled “**Affinity Maturation and Characterization of the Novel Monoclonal Antibody (mAb) PB-223 Targeting Cancer-Specific O-Glycans Terminating with $\alpha(2,6)$ Sialic Acids**“, has been published in the journal *CANCERS* on July 20th, 2026.

PB-223 is our lead monoclonal antibody (mAb). Highlights of the development of PB-223 described in this article include:

- Affinity maturation of NEO-102 (ensituximab) yielding PB-223 demonstrating more than a four-fold increase in binding to tumor-specific target
- Characterization of PB-223's target which is truncated Core-2 O-glycans
- Testing showing PB-223 does not bind to normal healthy human tissues
- Increased numbers of tumor types and cancer tissues recognized by binding with PB-223 compared to NEO-102
- Test results confirming internalization of PB-223 into tumor cells

Link to article:

<https://www.mdpi.com/2072-6694/18/14/2336>